Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials

J Hum Hypertens. 2005 Nov;19(11):855-9. doi: 10.1038/sj.jhh.1001933.

Authors

C J Boos¹, G Y H Lip

Affiliation

¹ Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK. [email protected]

PMID: 16094406
DOI: 10.1038/sj.jhh.1001933

No abstract available

MeSH terms

Angiotensin II Type 2 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use*
Atrial Fibrillation / etiology
Atrial Fibrillation / physiopathology*
Atrial Fibrillation / prevention & control*
Humans
Hypertension / complications
Hypertension / physiopathology*
Renin-Angiotensin System*

Substances

Angiotensin II Type 2 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents